常山药业 (300255.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−83.4x

Market Cap

CNY 21.49B

MomentumView details →

1D Return

−4.69%

YTD Return

−62.66%

RSI (14)

39.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−83.4x

Market Cap

CNY 21.49B

RSI (14)

39.0

MomentumView details →

1D Return

−4.69%

YTD Return

−62.66%

ProfitabilityView details →

Gross Margin

15.55%

Net Margin

−40.78%

EBITDA Margin

−32.19%

ROE (TTM)

−29.40%

ROA (TTM)

−8.02%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

−12.33%

EPS YoY

—

FCF YoY

+13.77%

Revenue CAGR 3Y

−27.91%

EPS CAGR 3Y

−44.44%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.93x

Current Ratio

0.74x

Quick Ratio

0.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

−80.77%

Financials snapshotView financials →

Revenue (TTM)

872.53M

Net Income (TTM)

−355.81M

Op. CF (TTM)

−27.10M

Latest newsMore news →

Changshan Pharmaceutical announced that its dalteparin sodium injection was provisionally selected in the 12th batch of national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.33d ago

Similar companies

吉林敖东000623.SZ 航天发展000547.SZ 众生药业002317.SZ 宏达电子300726.SZ 华测导航300627.SZ 乐普医疗300003.SZ Find similar companies →

Latest newsMore news →

Changshan Pharmaceutical announced that its dalteparin sodium injection was provisionally selected in the 12th batch of national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.33d ago